Objective to evaluate the serum NT-pro-brain natriuretic peptide in different subgroup of the subclinical thyroid dysfunction. Methods the study included 122 patients to be in hospital in the department of endocrinology and cardiology from the year 2002 to 2010,who,on the basis of plama levels of TSH,were divided intoA: Subclinical hypothyroidism 1(TSH4.5—9.9mU/L)(n=26)B: Subclinical hypothyroidism 2(TSH≥10mU/L)(n=30)C: Subclinical hyperthyroidism 1(TSH≥0.1,﹤0.45mU/L)(n=24)D: Subclinical hyperthyroidism 2(TSH﹤0.1mU/L)(n=21)E:control subjects with normal thyroid profile TSH(0.45—4.5 mU/L)(n=21),to evaluate the serum NT-pro-brain natriuretic peptide. Result compared to control subjects, Subclinical hyperthyroidism were characterized by higher serum NT-pro-brain natriuretic peptide ,this increase was particularly pronounced in Subclinical hyperthyroidism 2(TSH﹤0.1mU/L)compared to Subclinical hyperthyroidism 1(TSH≥0.1,﹤0.45mU/L), serum NT-pro-brain natriuretic peptide did not differ between patients in Subclinical hypothyroidism,nerither 1(TSH4.5—9.9mU/L)nor 2(TSH≥10mU/L),there is no associativity of the serum NT-pro-brain natriuretic peptide in different BMI index,blood-fasting sugarand ventriculus sinister weight index . Conclusions the risk of heart failure is increased when TSH﹤0.1mU/L in Subclinical hyperthyroidism. |